2023 Was a troublesome calendar year for that biopharma sector, with a number of firms downsizing and restructuring their workforces to remain afloat. You can find indications of recovery, as mergers and acquisitions picked up through the pharmaceutical and life sciences industry in the latter part of 2023 and also https://sites.google.com/view/bio-sites/blog